Eloxx Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Eloxx Pharmaceuticals

10/11/2022 23:44

* Eloxx Pharmaceuticals Inc  ELOX.OQ  reported a quarterly
adjusted loss of 9 cents​​ per share for the quarter ended in
September. The lone analyst forecast for the quarter was for a
loss of 11 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Eloxx Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 9 cents​.
    * The mean earnings estimate of analysts had risen by
about 10.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Eloxx Pharmaceuticals Inc shares had fallen by 32.5% this
quarter and lost 83.7% so far this year.
    * The company reported a quarterly loss of $7.51 million.
    * Wall Street's median 12-month price target for Eloxx
Pharmaceuticals Inc is $3.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 11:44 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.11          -0.09          Beat
 Jun. 30 2022      -0.10          -0.12          Missed
 Mar. 31 2022      -0.09          -0.13          Missed
 Dec. 31 2021      -0.12          -0.14          Missed